JP2012533587A5 - - Google Patents

Download PDF

Info

Publication number
JP2012533587A5
JP2012533587A5 JP2012520958A JP2012520958A JP2012533587A5 JP 2012533587 A5 JP2012533587 A5 JP 2012533587A5 JP 2012520958 A JP2012520958 A JP 2012520958A JP 2012520958 A JP2012520958 A JP 2012520958A JP 2012533587 A5 JP2012533587 A5 JP 2012533587A5
Authority
JP
Japan
Prior art keywords
seq
module
cell
compound
conjugate according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012520958A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012533587A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/004512 external-priority patent/WO2011009624A1/en
Publication of JP2012533587A publication Critical patent/JP2012533587A/ja
Publication of JP2012533587A5 publication Critical patent/JP2012533587A5/ja
Pending legal-status Critical Current

Links

JP2012520958A 2009-07-22 2010-07-22 自然に存在する細胞内輸送経路を介して化合物を送達するための送達システム及びコンジュゲート Pending JP2012533587A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22766909P 2009-07-22 2009-07-22
US61/227,669 2009-07-22
PCT/EP2010/004512 WO2011009624A1 (en) 2009-07-22 2010-07-22 Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes

Publications (2)

Publication Number Publication Date
JP2012533587A JP2012533587A (ja) 2012-12-27
JP2012533587A5 true JP2012533587A5 (https=) 2013-09-12

Family

ID=42731966

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012520958A Pending JP2012533587A (ja) 2009-07-22 2010-07-22 自然に存在する細胞内輸送経路を介して化合物を送達するための送達システム及びコンジュゲート

Country Status (5)

Country Link
US (1) US20120258104A1 (https=)
EP (1) EP2456470A1 (https=)
JP (1) JP2012533587A (https=)
CA (1) CA2768598A1 (https=)
WO (1) WO2011009624A1 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
RU2593715C2 (ru) 2010-09-15 2016-08-10 Рэндэлл Дж. МРСНИ Системы и способы доставки биоактивных средств с применением транспортных последовательностей, происходящих от бактериального токсина
CA2818173C (en) 2010-11-30 2022-05-03 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
US20140065172A1 (en) * 2011-01-26 2014-03-06 Cenix Bioscience Gmbh Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
WO2012113413A1 (en) * 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
US9045750B2 (en) * 2011-03-18 2015-06-02 Yuelong Ma Humanized lewis-Y specific antibody-based delivery of dicer substrate siRNA (D-siRNA) against STAT3
AU2012308320C1 (en) * 2011-09-14 2018-08-23 Translate Bio Ma, Inc. Multimeric oligonucleotide compounds
CN104039961A (zh) * 2012-01-07 2014-09-10 株式会社博纳克 具有氨基酸骨架的单链核酸分子
WO2013127829A1 (en) * 2012-02-27 2013-09-06 Universitat De Barcelona Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs
SG11201407483YA (en) 2012-05-16 2014-12-30 Rana Therapeutics Inc Compositions and methods for modulating smn gene family expression
EA201492116A1 (ru) 2012-05-16 2015-05-29 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии mecp2
EA201492122A1 (ru) 2012-05-16 2015-10-30 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии utrn
AU2013262699A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating ATP2A2 expression
BR112014028631A2 (pt) 2012-05-16 2017-10-17 Rana Therapeutics Inc composições e métodos para modulação da expressão da família de genes da hemoglobina
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
WO2013180038A1 (ja) 2012-05-26 2013-12-05 株式会社ボナック デリバリー機能を有する遺伝子発現制御用の一本鎖核酸分子
US20150247141A1 (en) 2012-09-14 2015-09-03 Rana Therapeutics, Inc. Multimeric oligonucleotide compounds
EP3666795A1 (en) 2013-03-12 2020-06-17 Molecular Templates, Inc. Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
EP3035969B1 (en) 2013-08-19 2022-08-03 S.M. Discovery Holdings Inc. Peptidic nanodelivery composition targeting two receptors
BR112016003361A2 (pt) 2013-08-21 2017-11-21 Curevac Ag vacina do vírus sincicial respiratório (rsv)
WO2015051283A1 (en) 2013-10-04 2015-04-09 Rana Therapeutics, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
WO2015099122A1 (ja) 2013-12-26 2015-07-02 学校法人東京医科大学 遺伝子発現制御のための人工ミミックmiRNAおよびその用途
CN106068324B (zh) 2013-12-27 2020-12-29 株式会社博纳克 控制基因表达的人工匹配型miRNA及其用途
CN112851769A (zh) 2014-01-27 2021-05-28 分子模板公司 用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
JP6935195B2 (ja) * 2014-03-11 2021-09-15 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 結合領域、志賀毒素aサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
EP3126501A1 (en) 2014-03-24 2017-02-08 RiboxX GmbH Double-stranded rna conjugates and their use
CN106470707A (zh) 2014-05-07 2017-03-01 应用分子运输有限责任公司 用于口服递送生物活性货物的cholix毒素衍生的融合分子
CN106604934A (zh) 2014-06-11 2017-04-26 分子模板公司 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
JP2017534598A (ja) * 2014-09-30 2017-11-24 ザ メディカル カレッジ オブ ウィスコンシン インクThe Medical College Of Wisconsin, Inc. 神経系疾患を治療する標的療法のための汎用的なプラットフォーム
US20170333571A1 (en) * 2014-11-04 2017-11-23 The Regents Of The University Of California Targeted Delivery Platform for Delivery of Therapeutics
KR20170098914A (ko) 2014-12-27 2017-08-30 가부시키가이샤 보낙 유전자 발현 제어를 위한 천연형 miRNA 및 그의 용도
EP3253799B1 (en) 2015-02-05 2020-12-02 Molecular Templates, Inc. Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
WO2016158809A1 (ja) 2015-03-27 2016-10-06 株式会社ボナック デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子
EP3303373B1 (en) 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
KR20180056750A (ko) * 2015-10-05 2018-05-29 신젠타 파티서페이션즈 아게 리보핵산의 생물학적 활성을 보존하는 방법
JP2019513371A (ja) * 2016-04-01 2019-05-30 アビディティー バイオサイエンシーズ エルエルシー 核酸ポリペプチド組成物とその使用
WO2018106895A1 (en) 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
MX2019008840A (es) 2017-01-25 2019-09-09 Molecular Templates Inc Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+.
AU2018378812B2 (en) 2017-12-06 2025-05-22 Avidity Biosciences, Inc. Compositions and methods of treating muscle atrophy and myotonic dystrophy
CN121513216A (zh) 2018-03-08 2026-02-13 应用分子转运公司 用于经口递送的毒素衍生的递送构建体
WO2019183600A1 (en) * 2018-03-23 2019-09-26 The Regents Of The University Of California Methods and compounds for targeted autophagy
CN110612117B (zh) 2018-04-17 2024-04-12 分子模板公司 包含去免疫化的志贺毒素a亚基支架的her2靶向分子
EP3818167A4 (en) * 2018-07-05 2022-04-13 The Regents of The University of California COMPOSITIONS AND METHODS FOR DELIVERING RNA TO A CELL
WO2020096695A1 (en) 2018-11-07 2020-05-14 Applied Molecular Transport Inc. Cholix-derived carriers for oral delivery of heterologous payload
EP4083058A3 (en) 2018-11-07 2023-01-11 Applied Molecular Transport Inc. Delivery constructs for transcytosis and related methods
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
EP3868882A1 (en) * 2020-02-21 2021-08-25 European Molecular Biology Laboratory Archaeal pyrrolysyl trna synthetases for orthogonal use
WO2021188390A1 (en) 2020-03-19 2021-09-23 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
WO2021216997A2 (en) * 2020-04-23 2021-10-28 Cornell University Nanotherapy targeting rhamm-positive tumors
CN118265544A (zh) 2021-09-16 2024-06-28 艾维迪提生物科学公司 治疗面肩肱型肌营养不良的组合物和方法
WO2023076820A1 (en) * 2021-10-26 2023-05-04 Navicure Biopharmaceuticals Limited Immunogenic fusion proteins against coronavirus
CN121378391B (zh) * 2025-12-24 2026-03-27 中国医学科学院药用植物研究所 具有抗肿瘤作用的龟源环肽化合物及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
WO1997013529A1 (en) * 1995-10-13 1997-04-17 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Immunotoxin containing a disulfide-stabilized antibody fragment
JP2001504334A (ja) * 1996-11-06 2001-04-03 アメリカ合衆国 プロテアーゼ活性化可能なPseudomonas体外毒素A様プロタンパク質
US6740643B2 (en) 1999-01-21 2004-05-25 Mirus Corporation Compositions and methods for drug delivery using amphiphile binding molecules
US8211468B2 (en) 1999-06-07 2012-07-03 Arrowhead Madison Inc. Endosomolytic polymers
AU2002236499A8 (en) 2000-11-30 2009-12-03 Uab Research Foundation Receptor-mediated uptake of peptides that bind the human transferrin receptor
DE60137969D1 (de) * 2000-12-21 2009-04-23 Us Gov Health & Human Serv Ein chimäres protein das nichttoxische pseudomonas exotoxin a und typ iv pilin sequenzen enthält
US20030133912A1 (en) 2001-12-11 2003-07-17 Davidson Beverly L. Receptor-targeted adenoviral vectors
ES2702942T3 (es) 2003-04-17 2019-03-06 Alnylam Pharmaceuticals Inc Agentes de ARNi modificados
US8017762B2 (en) 2003-04-17 2011-09-13 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
WO2005084158A2 (en) 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
US20100240597A1 (en) * 2007-06-15 2010-09-23 Arkansas State University Methods of delivery of molecules to cells using a ricin subunit and compositions relating to same
WO2009045457A2 (en) 2007-10-02 2009-04-09 Rxi Pharmaceuticals Corp. Tripartite rnai constructs

Similar Documents

Publication Publication Date Title
JP2012533587A5 (https=)
US8691580B2 (en) Single chemical entities and methods for delivery of oligonucleotides
Futaki et al. Cell-surface interactions on arginine-rich cell-penetrating peptides allow for multiplex modes of internalization
US20170137815A1 (en) Novel single chemical entities and methods for delivery of oligonucleotides
US10221205B2 (en) Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides
Varner et al. Recent advances in engineering polyvalent biological interactions
Yuan et al. A novel poly (L-glutamic acid) dendrimer based drug delivery system with both pH-sensitive and targeting functions
JP2012529891A5 (https=)
AU2019230230B2 (en) Toxin-derived delivery constructs for oral delivery
He et al. Combinatorial optimization of sequence-defined oligo (ethanamino) amides for folate receptor-targeted pDNA and siRNA delivery
JP2015526434A5 (https=)
CA2623659A1 (en) Targeted delivery of compounds using multimerization technology
EP3315139B1 (en) A delivery system for targeted delivery of a therapeutically active payload
KR101647804B1 (ko) 신규 세포투과 펩타이드 및 이의 용도
JP2022544882A (ja) ペイロード送達のための組成物および粒子
MX2013002939A (es) Sistemas y metodos de suministro de agentes bioactivos mediante el uso de secuencias transportadoras derivadas de toxinas.
Liu et al. Toward artificial immunotoxins: traceless reversible conjugation of RNase A with receptor targeting and endosomal escape domains
CN111093718A (zh) 治疗性纳米缀合物及其用途
US20140206596A1 (en) Design of pH-Sensitive Oligopeptide Complexes For Drug Release Under Mildly Acidic Conditions
CN112105376A (zh) 用于经口递送的毒素衍生的递送构建体
Gabathuler Development of new peptide vectors for the transport of therapeutic across the blood–brain barrier
Li et al. Targeted delivery of drugs for liver fibrosis
US20030068379A1 (en) Multifunctional carrier for the delivery of a pharmacological agent or genetic material into a cell
JP2022550901A (ja) 核酸治療薬のための腫瘍標的化ポリペプチドナノ粒子送達システム
CN113039194A (zh) 具有免疫调节特性的肽